Microdosing psychedelics—taking amounts too small to alter perception—is often reported to boost cognitive performance, but a remote testing study of 17 participants using a neurocognitive battery found no significant improvement or decline in processing speed, sustained attention, inhibitory control, set shifting, working memory, visual memory, or verbal memory on microdosing days or the day after. The results suggest that any perceived enhancement may stem from psychological rather than neurocognitive effects. Remote cognitive testing could facilitate larger, cross-cultural studies by easing participant burden.
Ibogaine, a powerful hallucinogen derived from the Iboga plant, is illegal in the United States but has been used in other countries to treat addiction. According to patient and provider sources, treatment typically involves 1–3 administrations. Farhad Garda of Ibogaine Therapy House in South Africa states that ibogaine's ability to interrupt the addiction cycle is beyond question. Ibogaine Pharma Ltd describes it as a new therapy for chemical dependence that eliminates physical withdrawal signs and interrupts drug craving behavior, acting as both a therapeutic and psychoactive addiction-breaker for drug and alcohol addictions.